Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Key Points

• Elanco raised its FY 2026 outlook, guiding adjusted EPS to $1.17–$1.20 versus the $1.13 analyst consensus and revenue to roughly $5.16–$5.18 billion versus about $5.1 billion expected.
• Third-quarter results beat estimates: adjusted EPS was $0.27 versus $0.20 expected, while revenue reached $1.265 billion, up 11% year over year.
• Shares rose 6.6% on Friday; analysts’ average rating was “Moderate Buy,” with an average price target of $29.33.

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.170-1.200 for the period, compared to the consensus estimate of 1.130. The company issued revenue guidance of $5.2 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q4 2026 guidance to 0.160-0.190 EPS.

Analyst Ratings Changes

ELAN has been the subject of several research analyst reports. UBS Group boosted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a research report on Friday, October 16th. They issued a "buy" rating and a $32.00 price objective on the stock. KeyCorp reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Finally, Morgan Stanley dropped their target price on Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating for the company in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of "Moderate Buy" and an average target price of $29.33.

Elanco Animal Health Trading Up 6.6%

NYSE:ELAN traded up $1.57 on Friday, hitting $25.25. 3,328,430 shares of the stock were exchanged, compared to its average volume of 5,580,573. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health has a 52 week low of $19.40 and a 52 week high of $27.98. The stock has a market capitalization of $12.62 billion, a price-to-earnings ratio of -61.59, a P/E/G ratio of 2.25 and a beta of 1.73. The company's 50-day moving average price is $23.11 and its 200 day moving average price is $23.82.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same quarter last year, the firm earned $0.19 EPS. The company's revenue for the quarter was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, equities research analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O'Neill bought 3,998 shares of the stock in a transaction on Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the acquisition, the insider owned 87,832 shares of the company's stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy J. Bettington sold 4,350 shares of the company's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider owned 138,911 shares of the company's stock, valued at $3,194,953. The trade was a 3.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have acquired 48,998 shares of company stock valued at $1,139,373. 1.14% of the stock is currently owned by corporate insiders.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS of $0.27 topped the $0.20 consensus estimate, and revenue of $1.265 billion exceeded expectations of about $1.21 billion. Revenue rose 11% year over year, with 9% organic constant-currency growth. Elanco third-quarter results
• Positive Sentiment: Elanco raised 2026 adjusted EPS guidance to $1.17–$1.20, above the $1.13 consensus, and lifted revenue guidance to $5.155–$5.18 billion versus approximately $5.1 billion expected. It also increased its innovation revenue target and improved its year-end net leverage target to about 2.9x adjusted EBITDA. Elanco third-quarter results
• Positive Sentiment: Company survey results suggest resilient consumer demand: 93% of surveyed pet owners maintained or increased pet spending over the prior three months, supporting the outlook for pet-health products. Elanco consumer research
• Neutral Sentiment: Fourth-quarter revenue guidance of $1.2 billion matches consensus. EPS guidance of $0.16–$0.19 has a midpoint of $0.175, just below the $0.18 estimate, though the range includes consensus. Elanco third-quarter results

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.